home / stock / arwr / arwr quote
Last: | $28.91 |
---|---|
Change Percent: | -0.97% |
Open: | $29.06 |
Close: | $28.91 |
High: | $29.06 |
Low: | $28.2252 |
Volume: | 641,722 |
Last Trade Date Time: | 07/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$28.91 | $29.06 | $28.91 | $29.06 | $28.2252 | 641,722 | 07-24-2024 |
$28.78 | $28.6 | $28.78 | $29.24 | $28.4567 | 656,535 | 07-23-2024 |
$28.75 | $28.47 | $28.75 | $28.9 | $27.83 | 742,532 | 07-22-2024 |
$28.3 | $27.75 | $28.3 | $28.31 | $27.29 | 735,247 | 07-19-2024 |
$27.64 | $28.02 | $27.64 | $28.99 | $27.22 | 967,822 | 07-18-2024 |
$28.02 | $28.7 | $28.02 | $28.97 | $27.73 | 1,317,187 | 07-17-2024 |
$29.54 | $28.98 | $29.54 | $30.41 | $28.77 | 1,394,144 | 07-16-2024 |
$28.86 | $28.31 | $28.86 | $29.0799 | $27.84 | 768,679 | 07-15-2024 |
$28.11 | $28.75 | $28.11 | $28.7595 | $27.9 | 809,668 | 07-12-2024 |
$28.25 | $27.64 | $28.25 | $28.79 | $27.19 | 1,547,121 | 07-11-2024 |
$26.82 | $25.4 | $26.82 | $26.83 | $25.09 | 936,164 | 07-10-2024 |
$25.35 | $25.55 | $25.35 | $26.19 | $25.2906 | 848,983 | 07-09-2024 |
$25.57 | $25.99 | $25.57 | $26.26 | $25.31 | 745,442 | 07-08-2024 |
$25.57 | $24.79 | $25.57 | $25.695 | $24.57 | 622,199 | 07-05-2024 |
$25.07 | $25.6 | $25.07 | $26 | $24.85 | 360,989 | 07-04-2024 |
$25.07 | $25.6 | $25.07 | $26 | $24.85 | 360,989 | 07-03-2024 |
$25.22 | $25.91 | $25.22 | $25.91 | $24.9 | 806,436 | 07-02-2024 |
$26.05 | $25.67 | $26.05 | $26.96 | $25.58 | 979,124 | 07-01-2024 |
$25.99 | $25.76 | $25.99 | $26.04 | $24.88 | 2,315,874 | 06-28-2024 |
$25.69 | $26.36 | $25.69 | $26.405 | $25.58 | 811,411 | 06-27-2024 |
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...